Evidence map›Paper›PMID 33713567›Full record

ArticleESC heart failure2021

Longitudinal profiling of circulating miRNA during cardiac allograft rejection: a proof-of-concept study.

Peter J Kennel, Alexandre Yahi, Yoshifumi Naka, Donna M Mancini, Charles C Marboe, Klaas Max, Kemal Akat, Thomas Tuschl, Elena-Rodica M Vasilescu, Emmanuel Zorn and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Peter J KennelDivision of Cardiology, Department of Medicine, Columbia University, New York, NY, USA.ORCID 0000-0002-7347-1298
Alexandre YahiDepartment of Biomedical Informatics, Columbia University, New York, NY, USA.
Yoshifumi NakaDepartment of Surgery, Columbia University, New York, NY, USA.
Donna M ManciniMount Sinai Heart, Mount Sinai Hospital, New York, NY, USA.
Charles C MarboeDepartment of Pathology and Cell Biology, Columbia University, New York, NY, USA.
Klaas MaxLaboratory of RNA Molecular Biology, Rockefeller University, New York, NY, USA.
Kemal AkatLaboratory of RNA Molecular Biology, Rockefeller University, New York, NY, USA.
Thomas TuschlLaboratory of RNA Molecular Biology, Rockefeller University, New York, NY, USA.
Elena-Rodica M VasilescuColumbia Center for Translational Immunology, Columbia University, New York, NY, USA.
Emmanuel ZornColumbia Center for Translational Immunology, Columbia University, New York, NY, USA.
Nicholas P TatonettiDepartment of Biomedical Informatics, Columbia University, New York, NY, USA.
Paul Christian SchulzeDepartment of Medicine I, Division of Cardiology, University Hospital of Friedrich Schiller University Jena, Am Klinikum 1, Jena, 07747, Germany.
Columbia University Irving Medical Center · USRockefeller University · USColumbia University · USCentre Alexandre Koyré · FRJena University Hospital · DEMount Sinai Hospital · USSt Nicholas Hospital · GB

Funding

Cardiac Lipotoxicity and Ceramide Metabolism in Heart FailureR01HL114813 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI COLOMBO, PAOLO C, SCHULZE, P. CHRISTIAN · 2013 to 2017
$3.0M
NHLBI NIH HHS R01 HL114813
6 · The paper itself

Abstract

aimsAllograft rejection following heart transplantation (HTx) is a serious complication even in the era of modern immunosuppressive regimens and causes up to a third of early deaths after HTx. Allograft rejection is mediated by a cascade of immune mechanisms leading to acute cellular rejection (ACR) and/or antibody-mediated rejection (AMR). The gold standard for monitoring allograft rejection is invasive endomyocardial biopsy that exposes patients to complications. Little is known about the potential of circulating miRNAs as biomarkers to detect cardiac allograft rejection. We here present a systematic analysis of circulating miRNAs as biomarkers and predictors for allograft rejection after HTx using next-generation small RNA sequencing. METHODS AND

resultsWe used next-generation small RNA sequencing to investigate circulating miRNAs among HTx recipients (10 healthy controls, 10 heart failure patients, 13 ACR, and 10 AMR). MiRNA profiling was performed at different time points before, during, and after resolution of the rejection episode. We found three miRNAs with significantly increased serum levels in patients with biopsy-proven cardiac rejection when compared with patients without rejection: hsa-miR-139-5p, hsa-miR-151a-5p, and hsa-miR-186-5p. We identified miRNAs that may serve as potential predictors for the subsequent development of ACR: hsa-miR-29c-3p (ACR) and hsa-miR-486-5p (AMR). Overall, hsa-miR-486-5p was most strongly associated with acute rejection episodes.

conclusionsMonitoring cardiac allograft rejection using circulating miRNAs might represent an alternative strategy to invasive endomyocardial biopsy.

Indexed as

Heart TransplantationMicroRNAsAllograftsBiomarkersGraft RejectionHumansBiomarkersMicroRNAsMIRN139 microRNA, humanMIRN186 microRNA, humanAllograft rejectionBiomarkerHeart transplantationMiRNA

Identifiers

PMID33713567
PMCPMC8120386
OpenAlexW3138437864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.